Clinical Trials Search at Vanderbilt-Ingram Cancer Center
Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors
Multiple Cancer Types
This is a Phase I multicenter, open label, nonrandomized study of enadenotucirev administered in combination with nivolumab in subjects with metastatic or advanced epithelial tumors (with focus on CRC, SCCHN, escalation phase), not responding to standard therapy.
Colon, Head/Neck, Lung, Non Small Cell, Rectal, Urologic